Navigation Links
Collagenase for Dupuytren's contracture: Added benefit not proven

Collagenase extracted from Clostridium histolyticum (trade name: Xiapex) was approved in the beginning of 2011 for the treatment of people with Dupuytren's contracture. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether collagenase offers an added benefit in comparison with conventional regimens. However, such an added benefit cannot be inferred from the dossier, as the drug manufacturer presented either no data or unsuitable data.

Collagenase is to break down thickened connective tissue fibres

Dupuytren's contracture is a disorder of the hand in which connective tissue fibres in the palmar side of the hand (fasciae) thicken and harden. As a result, one or several fingers become permanently bent and can no longer be straightened. Collagenase is injected into the lesions to break down the thickened connective tissue fibres. One day later, the rupture of these fibres through passive digital extension is attempted in order to restore the stretching ability of the affected finger.

G-BA specifies different comparator therapies depending on disease stage

When specifying the appropriate comparator therapy, the Federal Joint Committee (G-BA) assumed that the choice of (conventional) treatment depends on how severely the function of the fingers and hand is impaired.

Hence, the G-BA stipulates four treatment alternatives and assigns them to different disease stages. The appropriate comparator therapies are specified as follows:

  • no treatment" in stage N, where no contracture yet exists;
  • percutaneous needle fasciotomy" (PNF), a minimally invasive technique, in stages N/I, I and II;
  • partial fasciectomy" (PF), open surgery of the hand, in stages III and IV.

If PF is not suitable for advanced-stage patients, a PNF can be performed.

No assessment performed for three of four possible comparisons

However, the manufacturer deviated from the G-BA's specifications and chose PF as a comparator therapy for the whole indication. IQWiG regards this deviation to be insufficiently justified.

Regarding the G-BA's first, second and fourth research questions (patients with stage N, stages N/I, I and II, as well as patients with advanced stages for whom PF is not an option), the manufacturer neither performed any assessment nor indicated studies for such comparisons in the study list.

An added benefit for these three sub-indications is thus not proven.

Requirements for an indirect comparison not fulfilled

For the third research question (patients with stage III or IV without contraindications for PF), the manufacturer met the G-BA's specifications in the submitted dossier, choosing PF as the comparator therapy. However, there is no study available that directly compares PF and collagenase. As an alternative, the manufacturer presented data from an indirect comparison.

The legal ordinance on AMNOG explicitly allows for the option that added benefit may also be proven by means of such indirect comparisons. However, certain preconditions apply here, which the manufacturer did not fulfil. Due to a lack of suitable data, an added benefit is therefore not proven for this research question either.

G-BA decides on the extent of added benefit

The procedure for inferring the overall conclusion on the extent of added benefit is a proposal from IQWiG. The G-BA, which has opened a formal commenting procedure, decides on the extent of added benefit.

Contact: Dr. Anna-Sabine Ernst
Institute for Quality and Efficiency in Health Care

Related medicine news :

1. Abiraterone: Indication of considerable added benefit in certain patients
2. Nurse Alert Provides Added Level of Senior Alert Care With New Nurse Triage Feature
3. Tafamidis: Approval denotes proven added benefit
4. No Added Cancer Risk From Hip Replacement Materials: Study
5. Platelet drug shows clinical benefits for severe, unresponsive aplastic anemia
6. Green Tea Weight Loss Results and Health Benefits Revealed
7. Early Surgery May Benefit Some With Heart Infection
8. How much would our health benefit from leaving the car at home?
9. MTSS-mba Membership Benefits Administration Software for Private and Taft-Hartley Employee Benefit Funds Releases New Pension Modules
10. Some Diabetics May Not Benefit From Daily Aspirin
11. Tai Chi increases brain size, benefits cognition in randomized controlled trial of Chinese elderly
Post Your Comments:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... contact center software Q-Suite, announces the incorporation of Asterisk 11 LTS (Long Term ... fully supported Asterisk 11 LTS brings Q-Suite 5.10 up-to-date with a version of ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they also ... buy during the Black Friday and Cyber Monday massage chair sales to ... Internet high and low to find the best massage chair deals, they can see ...
(Date:11/26/2015)... , ... November 26, 2015 , ... ... Express Travel Representative. As a franchise owner, Somu now offers travelers, value and ... destination wedding packages, private cruise sales, as well as, cabin upgrades and special ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and ... offered by healthcare staffing agency Aureus Medical Group . These fields, ... 2015 among those searching for healthcare jobs through the company’s website, ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... opinion process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits ... place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... 2015  The American Academy of Pediatrics (AAP), ... the March of Dimes cheered today,s signature into ... Act of 2015 (S.799), which takes much-needed ... exposed to drugs, such as opioids, and to ... three organizations have worked together leading advocacy efforts ...
(Date:11/25/2015)... On Tuesday, November 24, 2015, the ... Wright Medical Technology, Inc. for product liability and ... implant device, awarded $11 million in favor of ... and three days of deliberations, the jury found ... designed and unreasonably dangerous, and that Wright Medical ...
Breaking Medicine Technology: